Which biologic agents are used in the treatment of cutaneous T-cell lymphoma (CTCL)?

Updated: Apr 20, 2020
  • Author: Lauren C Pinter-Brown, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Biologic agents such as interferon alfa and other cytokines (eg, IL-2), traditional and newer retinoids such as bexarotene, and receptor-targeted cytotoxic fusion proteins (eg, DAB389IL-2) are increasingly being used. The fusion protein, denileukin, was discontinued in January 2014. Combination therapy with bexarotene and PUVA should be considered for patients with treatment-resistant cutaneous T-cell lymphoma that is refractory to monotherapy. [117] However, the precise use of these newer treatments, either as single-agent therapy or in combination with other therapies (eg, PUVA) in the treatment of mycosis fungoides, remains to be established.

Beneficial results have been described with interferon alfa, either alone or in combination with PUVA therapy, prolonged treatment with a combination of low-dose chlorambucil (2-4 mg/day) and prednisone (10-20 mg/day), or methotrexate (MTX) (5-25 mg/wk), but complete responses are uncommon.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!